Balancing the Risk of Adverse Events against the Efficacy of Immunotherapy in Advanced Thymic Epithelial Tumors

SIMPLE SUMMARY: Treatment options for advanced thymic malignancies are limited. Immune checkpoint inhibitors are effective against advanced thymic epithelial tumors, but the treatment is associated with an elevated risk for adverse events. In this article, we aim to highlight new insights regarding...

Descripción completa

Detalles Bibliográficos
Autores principales: Ohm, Birte, Jungraithmayr, Wolfgang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9818983/
https://www.ncbi.nlm.nih.gov/pubmed/36612283
http://dx.doi.org/10.3390/cancers15010289

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9818983/
https://www.ncbi.nlm.nih.gov/pubmed/36612283
http://dx.doi.org/10.3390/cancers15010289

Ejemplares similares